Stephen H. Willard - 12 Jul 2022 Form 3 Insider Report for NRX Pharmaceuticals, Inc. (NRXP)

Reporting relationship: Chief Executive Officer, Director
Issuer ticker: NRXP
Reported as of: 12 Jul 2022
Net transaction value: $0
SEC form: 3
Accepted by SEC: 22 Jul 2022, 16:27:29 UTC
Next SEC filing: 19 Dec 2022
Source filing: View source filing
Reporting owner signature: /s/ Stephen Willard

Key filing fact

Stephen H. Willard filed Form 3 for NRX Pharmaceuticals, Inc. (NRXP) on 22 Jul 2022.

Key facts

This page summarizes Stephen H. Willard's Form 3 filing for NRX Pharmaceuticals, Inc. (NRXP).
0 reported transactions and 0 derivative rows are listed below.
Accepted by SEC: 22 Jul 2022, 16:27.

Change

No earlier filing in this sequence is available for direct comparison.
Current net transaction value: $0.

Research use

This tells you what this filing adds before you inspect full transaction and derivative tables.
You can trace every row back to the original SEC filing document.

Evidence

Official SEC source

Ownership activity is grounded in SEC Form 3 disclosures.

View source filing

Reported non-derivative transactions

Shares, units, or other non-derivative securities reported in this filing.

NRXP holding

Restricted Common Stock, par value $0.001 per share

No transaction description listed

Transaction value
Shares
Change %
Price
Shares after: 1,000,000
Date: 12 Jul 2022
Ownership: Direct
Footnotes: F1

^* marks a reported price that did not pass the local price check.

Additional SEC filing notes

Filing notes and footnotes

Explanation of responses 1 footnote

Footnote F1

Grant of an inducement award of 1,000,000 restricted shares of the Company's common stock. The restricted shares will vest in approximately equal installments over three (3) years from July 12, 2022, subject generally to the reporting person's continued service to the Company through the applicable vesting date.